Periodic Reporting for period 1 - T2Lead (Define a lead candidate for clinical development of a novel T cell therapy)

Patients suffering from Acute myeloid leukemia (AML) have a dismal outcome when relapsing or progressing after initial therapy. Unlike other hematological malignancies, cellular therapies such as chimeric antigen receptor (CAR) engineered T cells could not demonstrate efficacy...